COFACTOR
genomics

THE PROBLEM

Precision Medicine has failed us. 80% of cancer patients receive the wrong treatment.

Our new class of predictive diagnostics cuts this number in half.

With Predictive Immune Modeling, we believe that in the next 5 years, 90% of cancer patients can receive the right treatment.

Cofactor's unique diagnostic approach is built on the fact that our body's immune system is the most powerful defense we have against cancer.

MAKING AN IMPACT

Patients
1 million more patients per year correctly prescribed

Healthcare
$10 billion savings for payers by avoiding wrong treatments

Cofactor
$3 billion TAM in oncology immunotherapy market

PREDICTIVE DIAGNOSTICS

There has been a 500% increase in innovative new medicines, but diagnostic approaches (such as PD-L1 IHC) are failing and have created a Precision Medicine Gap.

Even the most innovative therapies, including immune checkpoint inhibitors, benefit only a subset of patients. Cofactor has built technology to play 'matchmaker' and bridge this gap.

INNOVATIVE THERAPIES	PREDICTIVE DIAGNOSTICS	PATIENTS

TECHNOLOGY

Our team of 20-year veterans in genomics, knowing the inherent limitations of DNA and protein assays, instead built the technologies, data assets, distribution, and regulatory frameworks to enable the power of RNA to build multidimensional biomarkers to predict treatment response. These biomarkers are the foundation for our OncoPrism™ diagnostic tests that enable clinicians to make more accurate patient treatment decisions.

INDUSTRY

Diagnostics, RNA, Precision Medicine, Oncology/Immune Oncology, Immunotherapy, Machine Learning, Patented Platform, Next Generation Sequencing, Laboratory Developed Tests, In Vitro Diagnostics

INVESTORS

Ascension Ventures, Stanford University, Menlo Ventures, DCVC, Y Combinator, Wilson-Sonsini, and others

FUNDING TO DATE
$17,500,000

BOARD

Jarret Glasscock, PhD - CEO
David Messina, PhD - COO
Jon Armstrong (Jumpcode)
Bill Hagstrom (Octave)
Mark Siegel (Menlo)
Armen Vidian (DCVC)
John Kuelper (Ascension)

LOCATION

San Francisco, CA (HQ)
St. Louis, MO
Boston, MA

EMAIL CONTACT
jarret@cofactorgenomics.com

ONCOLOGY ROADMAP

Successful results from studies across the most prevalent cancers has resulted in national expansion of our clinical trial with >15 contracted sites and clinical partners focused on >10 different cancers. Clinical leaders who set national guidelines and drive the future of oncology care have referred to Cofactor's technology as the 'holy grail' and what has been needed in oncology for a decade.

SELECT PARTNERS AND COLLABORATORS

MAYO CLINIC

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center

illumina®

Lilly

UC San Diego

Dayton Physicians Network

Washington University in St. Louis

genocea

Quest Diagnostics™

Ascension Sacred Heart

BCM
Baylor College of Medicine

FRED HUTCH
CURES START HERE

National Cancer Institute

JOHNS HOPKINS
MEDICINE

NATIONAL RESEARCH CENTERS

MultiCare
Institute for Research & Innovation

LEADERSHIP

Jarret Glasscock, PhD - CEO
Former Head of CompBio, Washington University Genome Sequencing Center. Published the first Cancer Genome. 20 year RNA computational analysis expert.

Natalie LaFranzo, PhD -
VP of Market Development
Broad commercial background in product marketing/management/sales; previous roles at Horizon Discovery & Red Rock Labs.

David Messina, PhD - COO
Complex Data Analyst, Microbiome/ Metagenomics. Developed first Commercial RNA-seq CAP/CLIA accreditation. CSHL Genome Informatics.

Dr. Eric Duncavage, MD - Medical Director
Board certified Clinical Diagnostic Pathologist, co-directs clinical assay development at Washington University in St. Louis, member of the clinical laboratory standards institute (CLSI).

COFACTOR AND RNA DIAGNOSTICS IN THE NEWS

[Cofactor Genomics Commences First Predictive Immune Modeling Clinical Trial to Bridge Precision Medicine Gap for Immunotherapy] Fifteen Institutions (including Mayo Clinic) Participate in Effort to Improve Patient Outcomes for Immune Checkpoint Inhibitors Across 11 Cancers

[Multivariate RNA Modeling Techniques Predicts Immune Checkpoint Responders] "Better tools are needed to provide clinicians and patients with a more accurate understanding of tumor response ahead of treatment decisions," explained Douglas Adkins, M.D., "The use of multidimensional biomarkers rather than single analyte biomarkers represents a promising new approach."

[Multidimensional Predictive Diagnostics: The GPS of Clinical Practice] Moving Beyond a Static Roadmap for Diagnostics - Cofactor's technology is highlighted in the April 2021 issue of the Journal of Precision Medicine

[Cofactor Genomics Cements Clinical Diagnostic Plans as Immunotherapy Prediction Data Build] GenomeWeb highlights Cofactor's expansion of potential clinical applications for its immune modeling technology

[New Data Published from Women & Infants Hospital Demonstrate Utility of Predictive Immune Modeling in Ovarian Cancer] Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer